Trial Profile
ASSESSMENT OF EARLY CHANGES OBSERVABLE IN DIFFUSION MRI IN RESPONSE TO TYSABRI TREATMENT TO TWO YEARS IN PATIENTS WITH MULTIPLE SCLEROSIS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2020
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms TYSADIFF
- 20 Dec 2020 Status changed from recruiting to completed.
- 06 Aug 2015 New trial record